
    
      This is a phase 1 single center, randomized, double-masked, parallel-group clinical trial.
      The primary objective is to assess the pharmacokinetics similarity of single and subcutaneous
      injection of CMAB807 injection or Prolia速 in health volunteers. The secondary objectives are
      to assess the clinical safety and immnogenicity similarity of single and subcutaneous
      injection of CMAB807 or Prolia速 in healty volunteers. Meanwhile, exploring the
      pharmacodynamic similarities of CMAB807 and Prolia速.

      Subjects will receive a single 60mg of CMAB807 or Prolia速 through subcutaneous injection.
    
  